Skip to main content

Table 3 OCS dose titration schedule during the reduction phase

From: SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma

 

OCS dose per day, mg

Optimized dose at week 0

Week

4

8

12

16

20

24

28

32

36

30.0

25.0

20.0

15.0

10.0

7.5

5.0

2.5

0.0

0.0

25.0

20.0

15.0

10.0

7.5

5.0

2.5

0.0

0.0

0.0

20.0

15.0

10.0

7.5

5.0

2.5

0.0

0.0

0.0

0.0

15.0

10.0

7.5

5.0

2.5

0.0

0.0

0.0

0.0

0.0

12.5

7.5

5.0

2.5

0.0

0.0

0.0

0.0

0.0

0.0

10.0

7.5

5.0

2.5

0.0

0.0

0.0

0.0

0.0

0.0

7.5

5.0

2.5

0.0

0.0

0.0

0.0

0.0

0.0

0.0

  1. OCS Oral corticosteroid